About BOS complex subunit NOMO2
BOS complex subunit NOMO2 (NOMO2) is a protein
from Homo sapiens identified by UniProt accession
Q5JPE7, 1267 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | BOS complex subunit NOMO2 |
|---|
| UniProt accession | Q5JPE7 |
|---|
| Gene | NOMO2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1267 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (11)
Diseases linked to this target (Open Targets).
- smoking status measurement · score 0.09
- attention deficit hyperactivity disorder · score 0.07
- substance abuse · score 0.07
- antisocial behaviour measurement · score 0.07
- PHF-tau measurement · score 0.05
- smoking behavior · score 0.05
- visual perception measurement · score 0.04
- smoking initiation · score 0.04
- neoplasm · score 0.00
- qualitative or quantitative defects of dystrophin · score 0.00
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5JPE7-F1 | alphafold | PREDICTED | 79.45 | — |
Amino-acid sequence (1267 residues)
MLVGQGAGLL GPAVVTAAVV LLLSGVGPAH GSEDIVVGCG GFVKSDVEIN YSLIEIKLYT KHGTLKYQTD CAPNNGYFMI PLYDKGDFIL KIEPPLGWSF EPTTVELHVD GVSDICTKGG DINFVFTGFS VNGKVLSKGQ PLGPAGVQVS LRNTGTEAKI QSTVTQPGGK FAFFKVLPGD YEILATHPTW ALKEASTTVR VTNSNANAAS PLIVAGYNVS GSVRSDGEPM KGVKFLLFSS LVTKEDVLGC NVSPVPGFQP QDESLVYLCY TVSREDGSFS FYSLPSGGYT VIPFYRGERI TFDVAPSRLD FTVEHDSLKI EPVFHVMGFS VTGRVLNGPE GDGVPEAVVT LNNQIKVKTK ADGSFRLENI TTGTYTIHAQ KEHLYFETVT IKIAPNTPQL ADIVATGFSV CGRISIIRFP DTVKQMNKYK VVLSSQDKDK SLVTVETDAH GSFCFKAKPG TYKVQVMVPE AETRAGLTLK PQTFPLTVTD RPVMDVAFVQ FLASVSGKVS CLDTCGDLLV TLQSLSRQGE KRSLQLSGKV NAMTFTFDNV LPGKYKISIM HEDWCWKNKS LEVEVLEDDV SAVEFRQTGY MLRCSLSHAI TLEFYQDGNG RENVGIYNLS KGVNRFCLSK PGVYKVTPRS CHRFEQAFYT YDTSSPSILT LTAIRHHVLG TITTDKMMDV TVTIKSSIDS EPALVLGPLK SVQELRREQQ LAEIEARRQE REKNGNEEGE ERMTKPPVQE MVDELQGPFS YDFSYWARSG EKITVTPSSK ELLFYPPSME AVVSGESCPG KLIEIHGKAG LFLEGQIHPE LEGVEIVISE KGASSPLITV FTDDKGAYSV GPLHSDLEYT VTSQKEGYVL TAVEGTIGDF KAYALAGVSF EIKAEDDQPL PGVLLSLSGG LFRSNLLTQD NGILTFSNLS PGQYYFKPMM KEFRFEPSSQ MIEVQEGQNL KITITGYRTA YSCYGTVSSL NGEPEQGVAM EAVGQNDCSI YGEDTVTDEE GKFRLRGLLP GCVYHVQLKA EGNDHIERAL PHHRVIEVGN NDIDDVNIIV FRQINQFDLS GNVITSSEYL PTLWVKLYKS ENLDNPIQTV SLGQSLFFHF PPLLRDGENY VVLLDSTLPR SQYDYILPQV SFTAVGYHKH ITLIFNPTRK LPEQDIAQGS YIALPLTLLV LLAGYNHDKL IPLLLQLTSR LQGVGALGQA ASDNSGPEDA KRQAKKQKTR RTLRLQEEFQ LMWCLVPWRG TLGIHLFSSL PFASEILLET TATCIHY
Explore BOS complex subunit NOMO2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets